Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-Controlled Study of Mometasone Furoate Nasal Spray in Seasonal Allergic Rhinitis
2014-004918-28Phase 3
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing Mometasone furoate nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Change from baseline in average AM/PM prior nasal congestion score (Days 1–15).
02
Drugs
mometasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2014-004918-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004918-28.